Gillian M Hunt1,2, E Kainne Dokubo3, Simbarashe Takuva1,2, Tulio de Oliveira4,5, Johanna Ledwaba1, Nomathemba Dube1, Pravi Moodley6, Jennifer Sabatier3, Varough Deyde7, Lynn Morris1,2, Elliot Raizes3. 1. Centre for HIV and STIs, National Institute for Communicable Diseases, Johannesburg, South Africa. 2. Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. 3. Division of Global HIV and TB, US Centers for Disease Control and Prevention, Atlanta, USA. 4. KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa. 5. Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa. 6. Department of Virology, National Health Laboratory Services/University of KwaZulu-Natal, South Africa. 7. US Centers for Disease Control and Prevention, Pretoria, South Africa.
Abstract
BACKGROUND: KwaZulu-Natal (KZN) Province in South Africa has the highest HIV disease burden in the country, with an estimated population prevalence of 24.7%. A pilot sentinel surveillance project was undertaken in KZN to classify the proportion of adult patients failing first-line ART and to describe the patterns of drug resistance mutations (DRMs) in patients with virological failure (VF). METHODS: Cross-sectional surveillance of acquired HIV drug resistance was conducted in 15 sentinel ART clinics between August and November 2013. Two population groups were surveyed: on ART for 12-15 months (Cohort A) or 24-36 months (Cohort B). Plasma specimens with viral load ≥1000 copies/mL were defined as VF and genotyped for DRMs. RESULTS: A total of 1299 adults were included in the analysis. The prevalence of VF was 4.0% (95% CI 1.8-8.8) among 540 adults in Cohort A and 7.7% (95% CI 4.4-13.0) of 759 adults in Cohort B. Treatment with efavirenz was more likely to suppress viral load in Cohort A (P = 0.005). Independent predictors of VF for Cohort B included male gender, advanced WHO stage at ART initiation and treatment with stavudine or zidovudine compared with tenofovir. DRMs were detected in 89% of 123 specimens with VF, including M184I/V, K103N/S, K65N/R, V106A/M and Y181C. CONCLUSIONS: VF in adults in KZN was <8% up to 3 years post-ART initiation but was associated with a high frequency of DRMs. These data identify key groups for intensified adherence counselling and highlight the need to optimize first-line regimens to maintain viral suppression.
BACKGROUND: KwaZulu-Natal (KZN) Province in South Africa has the highest HIV disease burden in the country, with an estimated population prevalence of 24.7%. A pilot sentinel surveillance project was undertaken in KZN to classify the proportion of adult patients failing first-line ART and to describe the patterns of drug resistance mutations (DRMs) in patients with virological failure (VF). METHODS: Cross-sectional surveillance of acquired HIV drug resistance was conducted in 15 sentinel ART clinics between August and November 2013. Two population groups were surveyed: on ART for 12-15 months (Cohort A) or 24-36 months (Cohort B). Plasma specimens with viral load ≥1000 copies/mL were defined as VF and genotyped for DRMs. RESULTS: A total of 1299 adults were included in the analysis. The prevalence of VF was 4.0% (95% CI 1.8-8.8) among 540 adults in Cohort A and 7.7% (95% CI 4.4-13.0) of 759 adults in Cohort B. Treatment with efavirenz was more likely to suppress viral load in Cohort A (P = 0.005). Independent predictors of VF for Cohort B included male gender, advanced WHO stage at ART initiation and treatment with stavudine or zidovudine compared with tenofovir. DRMs were detected in 89% of 123 specimens with VF, including M184I/V, K103N/S, K65N/R, V106A/M and Y181C. CONCLUSIONS: VF in adults in KZN was <8% up to 3 years post-ART initiation but was associated with a high frequency of DRMs. These data identify key groups for intensified adherence counselling and highlight the need to optimize first-line regimens to maintain viral suppression.
Authors: Jaysingh Brijkumar; Johnathan A Edwards; Brent A Johnson; Claudia Ordonez; Henry Sunpath; Mitch Lee; Mathew R Dudgeon; Lydia Rautman; Selvan Pillay; Pravi Moodley; Y V Sun; José Castillo-Mancilla; Jonathan Z Li; Daniel R Kuritzkes; Mohamed Y S Moosa; Vincent Charles Marconi Journal: HIV Med Date: 2022-01-12 Impact factor: 3.094
Authors: Lauren Jennings; Tracy Kellermann; Matthew Spinelli; Zukiswa Nkantsu; Dolphina Cogill; Marije van Schalkwyk; Eric Decloedt; Gert van Zyl; Catherine Orrell; Monica Gandhi Journal: AIDS Res Hum Retroviruses Date: 2021-12-29 Impact factor: 1.723
Authors: George Awungafac; Elvis T Amin; Akemfua Fualefac; Noah F Takah; Lucy A Agyingi; Julius Nwobegahay; Pascale Ondoa; Patrick A Njukeng Journal: PLoS One Date: 2018-06-11 Impact factor: 3.240
Authors: Kathleen Kehoe; Andrew Boulle; Priscilla R Tsondai; Jonathan Euvrard; Mary Ann Davies; Morna Cornell Journal: J Int AIDS Soc Date: 2020-05 Impact factor: 5.396
Authors: J Gregson; S Y Rhee; R Datir; D Pillay; C F Perno; A Derache; R S Shafer; R K Gupta Journal: J Infect Dis Date: 2020-09-01 Impact factor: 5.226
Authors: Giovanni Villa; Richard O Phillips; Colette Smith; Alexander J Stockdale; Alessandra Ruggiero; Apostolos Beloukas; Lambert T Appiah; David Chadwick; Fred S Sarfo; Anna Maria Geretti Journal: J Antimicrob Chemother Date: 2018-11-01 Impact factor: 5.790
Authors: Sheri A Lippman; Alyssa C Mooney; Adrian Puren; Gillian Hunt; Jessica S Grignon; Lisa M Prach; Hailey J Gilmore; Hong-Ha M Truong; Scott Barnhart; Teri Liegler Journal: BMC Infect Dis Date: 2020-03-26 Impact factor: 3.090